The CSNK1A1 antibody targets Casein Kinase 1 Alpha 1 (CK1α), a serine/threonine protein kinase belonging to the CK1 family. This enzyme is ubiquitously expressed and plays critical roles in diverse cellular processes, including Wnt/β-catenin signaling, DNA repair, circadian rhythm regulation, and cell cycle control. CK1α phosphorylates substrates involved in pathways such as p53 stabilization, β-catenin degradation, and membrane receptor trafficking, making it a key regulator of cellular homeostasis. Dysregulation of CSNK1A1 has been linked to cancer, neurodegenerative diseases, and developmental disorders.
Antibodies against CSNK1A1 are widely used in research to study its expression, localization, and interaction partners. They enable techniques like Western blotting, immunohistochemistry, and immunofluorescence to visualize CK1α in tissues or cultured cells. Specificity and validation (e.g., knockout controls) are essential due to homology among CK1 isoforms. Some antibodies detect post-translational modifications or conformational states, aiding functional studies.
Therapeutic interest in CK1α has grown, particularly in cancer, where it modulates drug resistance pathways. Researchers also explore CK1α inhibitors, making CSNK1A1 antibodies valuable tools for preclinical evaluation. Commercial variants vary in host species (rabbit, mouse), clonality (monoclonal/polyclonal), and applications, requiring careful selection based on experimental needs.